ATL001 in Patients With Metastatic or Recurrent Melanoma
Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
This is a first-in-human, open-label, multi-centre, phase I/IIa study to characterize the
safety and clinical activity of ATL001, autologous clonal neoantigen reactive T cells (cNeT)
administered intravenously in adults with metastatic or recurrent melanoma.